Cell lines database

1,Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JKV, Hamilton S and Vogelstein B,1990, p53 Gene Mutations Occur in Combination with 17p Allelic Deletions As Late Events in Colorectal Tumorigenesis, Cancer Research,50, 7717-7722

3,Cheng J and Haas M,1990, Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines, Mol Cell Biol ,10, 5502-5509

5,Hollstein MC, Metcalf RA, Welsh JA, Montesano R and Harris CC,1990, Frequent Mutation of the p53 Gene in Human Esophageal Cancer, Proc Natl Acad Sci USA,24, 9958-9961

9,Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC and Vogelstein B,1989, Mutations in the P53 Gene Occur in Diverse Human Tumour Types, Nature,342, 705-708

12,Slingerland JM, Minden MD and Benchimol S,1991, Mutation of the p53-Gene in Human Acute Myelogenous Leukemia, Blood,77, 1500-1507

14,Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CDM, Ball A, Thomas M, Gusterson BA and Cooper CS,1990, Mutation of the P53 Gene in Human Soft Tissue Sarcomas - Association with Abnormalities of the Rb1 Gene, Oncogene,5, 1297-1301

17,Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD,1989, P53 - A Frequent Target for Genetic Abnormalities in Lung Cancer, Science,246, 491-494,

22,D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R, Gazdar A and Minna JD,1992, High Frequency of Somatically Acquired p53 Mutations in Small-Cell Lung Cancer Cell Lines and Tumors, Oncogene ,7, 339-346

24,Bartek J, Iggo R, Gannon J and Lane DP,1990, Genetic and Immunochemical Analysis of Mutant P53 in Human Breast Cancer Cell Lines, Oncogene ,5, 893-899

25,Romano JW, Ehrhardt JC, Duthu A, Kim CM, Appella E and May P,1989, Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line, Oncogene ,4, 1483-1488

27,Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV and Lane DP,1990, P53 mutations in colorectal cancer, Proc Natl Acad Sci USA ,87, 7555-7559

38,Murakami Y, Hayashi K and Sekiya T,1991, Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis, Cancer Res ,51, 3356-3361

44,Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM and Dallafavera R,1991, p53 Mutations in Human Lymphoid Malignancies - Association with Burkitt Lymphoma and Chronic Lymphocytic Leukemia, Proc Natl Acad Sci USA ,88, 5413-5417

46,Kim JH, Takahashi T, Chiba I, Park JG, Birrer MJ, Roh JK, Lee HD, Kim JP, Minna JD and Gazdar AF,1991, Occurrence of p53-Gene Abnormalities in Gastric Carcinoma Tumors and Cell Lines, J Nat Cancer Inst ,83, 938-943

47,Hensel CH, Xiang RH, Sakaguchi AY and Naylor SL,1991, Use of the Single Strand Conformation Polymorphism Technique and PCR to Detect p53 Gene Mutations in Small Cell Lung Cancer, Oncogene ,6, 1067-1071

54,Scheffner M, Munger K, Byrne JC and Howley PM,1991, The State of the p53 and Retinoblastoma Genes in Human Cervical Carcinoma Cell Lines, Proc Natl Acad Sci USA ,88, 5523-5527

55,Gupta RK, Patel K, Bodmer WF and Bodmer JG,1993, Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease, Proc. natl. Acad. Sci. USA ,90, 2817-2821

59,Isaacs WB, Carter BS and Ewing CM,1991, Wild-Type p53 Suppresses Growth of Human Prostate Cancer Cells Containing Mutant p53 Alleles, Cancer Res ,51, 4716-4720

64,Yaginuma Y and Westphal H,1991, Analysis of the p53 Gene in Human Uterine Carcinoma Cell Lines, Cancer Res ,51, 6506-6509

65,Brachman DG, Hallahan DE, Beckett MA, Yandell D and Weichselbaum RR,1991, p53 gene mutations and abnormal retinoblastoma protein in radiation induced human sarcomas, Cancer Res. ,51, 6393-6396

69,Cote RJ, Jhanwar SC, Novick S and Pellicer A,1991, Genetic Alterations of the p53 Gene Are a Feature of Malignant Mesotheliomas, Cancer Res ,51, 5410-5416

71,Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, Hirohashi S, Nakatani K, Nakano H, Sugimura T and Terada M,1991, p53 Gene Mutations in Gastric Cancer Metastases and in Gastric Cancer Cell Lines Derived from Metastases, Cancer Res ,51, 5800-5805

73,Saylors RL, Sidransky D, Friedman HS, Bigner SH, Bigner DD, Vogelstein B and Brodeur GM,1991, Infrequent p53 Gene Mutations in Medulloblastomas, Cancer Res ,51, 4721-4723

75,Farrell PJ, Allan G, Shanahan F, Vousden KH and Crook T,1991, p53 is frequently mutated in Burkitt's lymphoma cell lines, EMBO J ,10, 2879-2887

76,Kovach JS, Mcgovern RM, Cassady JD, Swanson SK, Wold LE, Vogelstein B and Sommer SS,1991, Direct Sequencing from Touch Preparations of Human Carcinomas - Analysis of p53 Mutations in Breast Carcinomas, J Nat Cancer Inst ,83, 1004-1009

82,Sugito S, Yamato K, Sameshima Y, Yokota J, Yano S and Miyoshi I,1991, Adult T-Cell Leukemia: Structures and Expression of the p53 Gene, Int J Cancer ,49, 880-885

83,Maehle L, Metcalf RA, Ryberg D, Bennett WP, Harris CC and Haugen A,1992, Altered p53 Gene Structure and Expression in Human Epithelial Cells After Exposure to Nickel, Cancer Res ,52, 218-221

84,Wright PA, Lemoine NR, Goretzki PE, Wyllie FS, Bond J, Hughes C, Roher HD, Williams ED and Wynfordthomas D,1991, Mutation of the p53-Gene in a Differentiated Human Thyroid Carcinoma Cell Line, But Not in Primary Thyroid Tumours, Oncogene ,6, 1693-1697

92,Mitsudomi T, Steinberg SM, Nau MM, Carbone D, Damico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD and Gazdar AF,1992, p53 Gene Mutations in Non-Small-Cell Lung Cancer Cell Lines and Their Correlation with the Presence of ras Mutations and Clinical Features, Oncogene ,7, 171-180

93,Davidoff AM, Pence JC, Shorter NA, Iglehart JD and Marks JR,1992, Expression of p53 in Human Neuroblastoma-Derived and Neuroepithelioma-Derived Cell Lines, Oncogene ,7, 127-133

94,Matozaki T, Sakamoto C, Matsuda K, Suzuki T, Konda Y, Nakano O, Wada K, Uchida T, Nishisaki H, Nagao M and Kasuga M,1992, Missense Mutations and a Deletion of the p53-Gene in Human Gastric Cancer, Biochem Biophys Res Commun ,182, 215-223

97,Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ and Helman LJ,1992, Frequency and Diversity of p53 Mutations in Childhood Rhabdomyosarcoma, Cancer Res ,52, 2243-2247

98,Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C and Klein B,1992, Mutations of the p53 Gene in Human Myeloma Cell Lines, Oncogene ,7, 1015-1018

105,Sakai E and Tsuchida N,1992, Most Human Squamous Cell Carcinomas in the Oral Cavity Contain Mutated p53 Tumor-Suppressor Genes, Oncogene ,7, 927-933

106,Bodner SM, Minna JD, Jensen SM, Damico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF and Linnoila RI,1992, Expression of Mutant p53 Proteins in Lung Cancer Correlates with the Class of p53 Gene Mutation, Oncogene ,7, 743-749

108,Effert P, Mccoy R, Abdelhamid M, Flynn K, Zhang Q, Busson P, Tursz T, Liu E and Raabtraub N,1992, Alterations of the p53 Gene in Nasopharyngeal Carcinoma, J Virol ,66, 3768-3775

126,Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y and Hirai H,1992, Frequent Mutations in the p53 Gene in Human Myeloid Leukemia Cell Lines, Blood ,79, 2378-2383

132,Ruggeri B, Zhang SY, Caamano J, Dirado M, Flynn SD and Kleinszanto AJP,1992, Human Pancreatic Carcinomas and Cell Lines Reveal Frequent and Multiple Alterations in the p53 and Rb-1 Tumor-Suppressor Genes, Oncogene ,7, 1503-1511

138,Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Gerwin BI and Harris CC,1992, P53 and kirsten-ras mutations in human mesothelioma cell lines, Cancer Res ,52, 2610-2615

144,Yaginuma Y and Westphal H,1992, Abnormal Structure and Expression of the p53 Gene in Human Ovarian Carcinoma Cell Lines, Cancer Res ,52, 4196-4199

145,Spruck CH, Tsai YC, Huang DP, Yang AS, Rideout WM, Gonzalezzulueta M, Choi P, Lo KW, Yu MC and Jones PA,1992, Absence of p53 gene mutations in primary nasopharyngeal carcinomas, Cancer Res ,52, 4787-4790

147,Runnebaum IB, Nagarajan M, Bowman M, Soto D and Sukumar S,1991, Mutations in p53 as potential molecular markers for human breast cancer, Proc Natl Acad Sci USA ,88, 10657-10661

150,Bi SC, Hughes T, Bungey J, Chase A, Defabritiis P and Goldman JM,1992, p53 in chronic myeloid leukemia cell lines, Leukemia ,6, 839-842

153,Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL and Casey G,1992, Frequent p53 mutations in head and neck cancer, Cancer Res ,52, 5997-6000

155,Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S and Itakura M,1992, Role of p53 mutations in endocrine tumorigenesis - mutation detection by polymerase chain Reaction-Single strand conformation polymorphism, Cancer Res ,52, 5061-5064

160,Jung M, Notario V and Dritschilo A,1992, Mutations in the p53 gene in Radiation-Sensitive and Radiation-Resistant human squamous carcinoma cells, Cancer Res ,52, 6390-6393

161,Duthu A, Debuire B, Romano J, Ehrhart JC, Fiscella M, May E, Appella E and May P,1992, p53 mutations in raji cells - characterization and localization relative to other burkitt's lymphomas, Oncogene ,7, 2161-2167

163,Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW,1991, Participation of p53 protein in the cellular response to DNA damage, Cancer Res ,51, 6304-6311

176,Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmüller G, Scherer E, Maurer J, Maacke H and Deppert W,1993, p53 and K-ras alterations in pancreatic epithelial cell lesions, Oncogene ,8, 289-298

177,Berrozpe G, Schaeffer J, Peinado MA, Real FX and Perucho M,1994, Comparative analysis of mutations in the p53 and k-ras genes in pancreatic cancer, Int J Cancer ,58, 185-191

178,Barton CM, Staddon SL, Hughes CM, Hall PA, Osullivan C, Kloppel G, Theis B, Russell RCG, Neoptolemos J, Williamson RCN, Lane DP and Lemoine NR,1991, Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer, Br. J. Cancer ,64, 1076-1082

188,Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH and Koeffler HP,1993, High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas, J Clin Invest ,91, 179-184

202,Caamano J, Zhang SY, Rosvold EA, Bauer B and Kleinszanto AJP,1993, p53 alterations in human squamous cell carcinomas and carcinoma cell lines, Am J Pathol ,142, 1131-1139

208,Burns JE, Baird MC, Clark LJ, Burns PA, Edington K, Chapman C, Mitchell R, Robertson G, Soutar D and Parkinson EK,1993, Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines, Br J Cancer ,67, 1274-1284

214,Reiter RE, Anglard P, Liu S, Gnarra JR and Linehan WM,1993, Chromosome-17p deletions and p53 mutations in renal cell carcinoma, Cancer Res ,53, 3092-3097

219,Peidano MA, Fernandez-Renart M, Capella G, Wilson L and Perucho M,1993, Mutations in the p53 suppressor gene do not correlate with c-K-ras oncogene mutations in colorectal cancer, Int. J. Oncol. ,2, 123-134

220,Effert PJ, Mccoy RH, Walther PJ and Liu ET,1993, p53 gene alterations in human prostate carcinoma, J Urol ,150, 257-261

226,Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, Salzerkuntschik M and Gadner H,1993, Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in ewing tumours, Oncogene ,8, 2683-2690

230,Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T and Harris CC,1993, p53 gene mutation and integrated Hepatitis-B viral DNA sequences in human liver cancer cell lines, Carcinogenesis ,14, 987-992

232,Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, Ponchel F, Yakicier C, Ji JW and Ozturk M,1993, Retinoblastoma and p53-Tumor suppressor genes in human hepatoma cell lines, FASEB J ,7, 1407-1413

233,Weiss J, Schwechheimer K, Cavenee WK, Herlyn M and Arden KC,1993, Mutation and expression of the p53 gene in malignant melanoma cell lines, Int J Cancer ,54, 693-699

239,Sotomatsu M, Hayashi Y, Kawamura M, Yugami S and Shitara T,1993, Establishment of a new human Pre-B-Acute lymphoblastic leukemia cell line (KMO-90) with 1;19 translocation carrying p53 gene alterations, Leukemia ,7, 1615-1620

243,Abo J, Inokuchi K, Dan K and Nomura T,1993, p53 and n-ras mutations in two new leukemia cell lines established from a patient with multilineage CD7-Positive acute leukemia, Blood ,82, 2829-2836

244,Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsh JA, Metcalf RA, Stampfer MR, Fusenig N, Rogan EM and Harris CC,1993, p53 mutations in human immortalized epithelial cell lines, Carcinogenesis ,14, 833-839

245,Komuro H, Hayashi Y, Kawamura M, Hayashi K, Kaneko Y, Kamoshita S, Hanada R, Yamamoto K, Hongo T, Yamada M and Tsuchida Y,1993, Mutations of the p53 gene are involved in ewings sarcomas but not in neuroblastomas, Cancer Res ,53, 5284-5288

269,Neubauer A, He M, Schmidt CA, Huhn D and Liu ET,1993, Genetic alterations in the p53 gene in the blast crisis of chronic myelogeneous leukemia - analysis by polymerase chain reaction based techniques, Leukemia ,7, 593-600

272,Hovig E, Andreassen A, Fangan BM and Borresen AL,1992, A TP53 mutation detected in cells established from an osteosarcoma, but not in the retinoblastoma of a patient with bilateral retinoblastoma and multiple primary osteosarcomas, Cancer Genet Cytogenet ,64, 178-182

277,Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJS, Friedmann T, Detribolet N and Cavenee WK,1994, Analysis of the p53 gene and its expression in human glioblastoma cells, Cancer Res ,54, 649-652

294,Williamson MP, Elder PA and Knowles MA,1994, The spectrum of tp53 mutations in bladder carcinoma, Gene Chromosome Cancer ,9, 108-118

303,Ramet M, Castren K, Jarvinen K, Pekkala K, Turpeenniemihujanen T, Soini Y, Paakko P and Vahakangas K,1995, p53 protein expression is correlated with benzo[alpha]pyrene-DNA adducts in carcinoma cell lines, Carcinogenesis ,16, 2117-2124

314,Bar-Eli M, Abbruzzese JL, Lee-Jackso D and Frost P,1993, p53 mutation spectrum in human unknown primary tumors, Anticancer Res ,13, 1619-1624

316,Carroll AG, Voeller HJ, Sugars L and Gelmann EP,1993, p53 oncogene mutations in three human prostate cancer cell lines, Prostate ,23, 123-134

323,Yeargin J, Cheng J, Yu AL, Gjerset R, Bogart M and Haas M,1993, P53 mutation in acute T-Cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T-Cell acute lymphoblastic leukemia cell lines, J Clin Invest ,91, 2111-2117

328,Hamelin R, Zucman J, Melot T, Delattre O and Thomas G,1994, P53 mutations in human tumors with chimeric Ews/Fli-1 genes, Int J Cancer ,57, 336-340

339,Enomoto T, Fujita M, Inoue M, Nakazawamiyamoto A, Tanizawa O and Nomura T,1993, Alterations of the rb gene and its association with ki-ras activation and p53 inactivation in endometrial adenocarcinoma, Mol Carcinogen ,8, 132-137

347,Luca M, Lenzi R, Lee-Jackson D, Gutman M, Fidler IJ and Bar-Eli M,1993, p53 mutations are infrequent and do not correlate with the metastatic potential of human melanoma cells, Int. J. Oncol. ,3, 19-22

356,Chang Y-S, Lin Y-J, Tsai C-N, Shu C-H, Tsai M-S, Choo K-B and Liu S-T,1992, Detection of mutations in the p53 gene in human head and neck carcinomas by single strand conformation polymorphism analysis, Cancer Letters ,67, 167-174

364,Kashii T, Mizushima Y, Monno S, Nakagawa K and Kobayashi M,1994, Gene analysis of K-ras, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain Reaction/Single-Strand conformation polymorphism method, J Cancer Res Clin Oncol ,120, 143-148

370,Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P and Westphal M,1993, p53-Protein accumulation and gene mutations in human glioma cell lines, Int J Cancer ,55, 982-987

376,Runnebaum IB, Tong XW, Moebus V, Heilmann V, Kieback DG and Kreienberg R,1994, Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines, Hum Genet ,93, 620-624

397,Redston MS, Caldas C, Seymour AB, Hruban RH, Dacosta L, Yeo CJ and Kern SE,1994, p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions, Cancer Res ,54, 3025-3033

416,Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM and Chrousos GP,1994, P53 mutations in human adrenocortical neoplasms - immunohistochemical and molecular studies, J Clin Endocrinol Metab ,78, 790-794

418,Burns JE, Clark LJ, Yeudall WA, Mitchell R, Mackenzie K, Chang SE and Parkinson EK,1994, The p53 status of cultured human premalignant oral keratinocytes, Br J Cancer ,70, 591-595

428,Simon B, Weinel R, Hohne M, Watz J, Schmidt J, Kortner G and Arnold R,1994, Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma, Gastroenterology ,106, 1645-1651

440,Suwa H, Yoshimura T, Yamaguchi N, Kanehira K, Manabe T, Imamura M, Hiai H and Fukumoto M,1994, K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines, Jpn J Cancer Res ,85, 1005-1014

447,O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I and Kohn KW,1993, Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of burkitts lymphoma cell lines, Cancer Res ,53, 4776-4780

462,Nabeya Y, Loganzo F, Maslak P, Lai L, Deoliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP and Albino AP,1995, The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents, Int J Cancer ,64, 37-46

468,Horikawa I, Suzuki M, Yoshida MA and Oshimura M,1995, Frame-shift mutation and reduced transcript of p53 gene in a renal cell carcinoma cell line, RCC23, Hum Mol Genet ,4, 771-773

469,Demers GW, Halbert CL and Galloway DA,1994, Elevated Wild-Type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene, Virology ,198, 169-174

472,Russell SJ, Ye YW, Waber PG, Shuford M, Schold SC and Nisen PD,1995, P53 mutations, o-6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors, Cancer ,75, 1339-1342

473,Yaginuma Y, Yamashita T, Takuma N, Katayama H and Ishikawa M,1995, Analysis of the p53 gene in human choriocarcinoma cell lines, Br J Cancer ,71, 9-12

474,Matsumoto H, Shimura M, Omatsu T, Okaichi K, Majima H and Ohnishi T,1994, p53 proteins accumulated by heat stress associate with heat shock proteins HSP72/HSC73 in human glioblastoma cell lines, Cancer Letters ,87, 39-46

478,Kawamura M, Kikuchi A, Kobayashi S, Hanada R, Yamamoto K, Horibe K, Shikano T, Ueda K, Hayashi K, Sekiya T and Hayashi Y,1995, Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia, Blood ,85, 2546-2552

491,Tada M, Iggo RD, Ishii N, Shinohe Y, Sakuma S, Estreicher A, Sawamura Y and Abe H,1996, Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay, Int J Cancer ,67, 447-450

492,Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G and Summerhayes IC,1995, Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression, Oncogene ,11, 647-652

517,Chang H, Blondal JA, Benchimol S, Minden MD and Messner HA,1995, p53 mutations, c-myc and bcl-2 rearrangements in human non-hodgkin's lymphoma cell lines, Leuk Lymphoma ,19, 165-171

552,Madsen MW, Moyret C, Theillet C and Briand P,1995, Growth factor requirement, oncogene expression and TP53 mutations of a tumorigenic and a non-tumorigenic subline of the human breast carcinoma cell line, HMT-3909, Eur J Cancer ,31A, 362-367

561,Cooper MJ, Halushak JJ, Johnson D, Schwarz S, Morrison LJ, Lippa M, Hatzivassiliou G and Tan J,1994, p53 mutations in bladder carcinoma cell lines, Oncology Res. ,6, 569-579

564,Cheng YT, Li YL, Wu JD, Long SB, Tzai TS, Tzeng CC and Lai MD,1995, Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines, Mol Carcinogen ,13, 173-181

573,Fogel S, Ahomadegbe J-C, Bihan M-L, Le Bihan ML, Barois M and Riou G,1995, Characterization of a new p53-mutated and HPV-negative human squamous cell cervical carcinoma-derived cell line, Int. J. Oncol. ,6, 681-686

589,Ohnishi H, Kawamura M, Hanada R, Kaneko Y, Tsunoda Y, Hongo T, Bessho F, Yokomori K and Hayashi Y,1996, Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas, Gene Chromosome Cancer ,15, 187-190

590,Runnebaum IB, Tong XW, Mobus VJ, Kieback DG, Rosenthal HE and Kreienberg R,1994, p53 mutant His175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6, FEBS Lett ,353, 29-32

598,Inagaki T, Matsuwari S, Takahashi R, Shimada KK, Fujie K and Maeda S,1994, Establishment of human Oral-Cancer cell lines (KOSC-2 and KOSC-3) carrying p53 and c-myc abnormalities by geneticin treatment, Int J Cancer ,56, 301-308

600,Xu L, Davidson BJ, Murty VVVS, Li RG, Sacks PG, Garinchesa P, Schantz SP and Chaganti RSK,1994, TP53 gene mutations and CCND1 gene amplification in head and neck squamous cell carcinoma cell lines, Int J Cancer ,59, 383-387

606,Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F,1996, Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems, Cancer Res ,56, 556-562

613,Farrugia MM, Duan LJ, Reis MD, Ngan BY and Berinstein NL,1994, Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-myc and bcl-2 Proto-Oncogenes, Blood ,83, 191-198

617,Zhou MX, Yeager AM, Smith SD and Findley HW,1995, Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene, Blood ,85, 1608-1614

626,Min B-M, Baek J-H, Shin K-H, Gujuluva CN, Cherrick HM and Park N-H,1994, Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines, Oral Oncol. Eur. J. Cancer ,30B, 338-345

632,Fujiwara T, Mukhopadhyay T, Cai DW, Morris DK, Roth JA and Grimm EA,1994, Retroviral-Mediated transduction of p53 gene increases TGF-beta expression in a human glioblastoma cell line, Int J Cancer ,56, 834-839

634,Tanaka H, Shibagaki I, Shimada Y, Wagata T, Imamura M and Ishizaki K,1996, Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors, Int J Cancer ,65, 372-376

635,Tomita Y, Bilim V, Kawasaki T, Takahashi K, Okan I, Magnusson KP and Wiman KG,1996, Frequent expression of bcl-2 in renal-cell carcinomas carrying wild-type p53, Int J Cancer ,66, 322-325

637,Little JB, Nagasawa H, Keng PC, Yu YJ and Li CY,1995, Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status, J Biol Chem ,270, 11033-11036

659,Fralix KD, Ahmed MM, Mattingly C, Swiderski C, McGrath PC, Venkatasubbarao K, Kamada N, Mohiuddin M, Strodel WE and Freeman JW ,2000, Characterization of a newly established human pancreatic carcinoma cell line, UK Pan-1, Cancer ,88, 2010-21

661,Wada H, Asada M, Nakazawa SP, Itoh H, Kobayashi Y, Inoue T, Fukumuro K, Chan LC, Sugita K, Hanada R, Akuta N, Kobayashi N and Mizutani S,1994, Clonal expansion of p53 mutant cells in leukemia progression in vitro, Leukemia ,8, 53-59

664,Chen PC, Iavarone A, Fick J, Edwards M, Prados M and Israel MA,1995, Constitutional p53 mutations associated with brain tumors in young adults, Cancer Genet Cytogenet ,82, 106-115

678,Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn PA, Jr , Carney D, Minna JD and Mulshine JL ,1996, NCI-Navy Medical Oncology Branch cell line data base, J Cell Biochem Suppl ,24, 32-91

681,Hietanen SH, Kurvinen K, Syrjanen K, Grenman S, Carey T, Mcclatchey K and Syrjanen S,1995, Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells, Am J Obstet Gynecol ,173, 1477-1482

689,Grimm MO, Jurgens B, Schulz WA, Decken K, Makri D and Schmitzdrager BJ,1995, Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines, Urol Res ,23, 293-300

698,Martincic D and Whitlock JA,1996, Improved detection of p53 point mutations by dideoxyfingerprinting (DdF), Oncogene ,13, 2039-2044

724,Cottu PH, Muzeau F, Estreicher A, Flejou JF, Iggo R, Thomas G and Hamelin R,1996, Inverse correlation between RER(+) status and p53 mutation in colorectal cancer cell lines, Oncogene ,13, 2727-2730

729,Rieger KM, Little AR, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT, Libertino JA and Summerhayes IC,1995, Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression, Br J Cancer ,72, 683-690

747,Park JG, Yang HK, Kim WH, Chung JK, Kang MS, Lee JH, Oh JH, Park HS, Yeo KS, Kang SH, Song SY, Kang YK, Bang KJ, Kim YI and Kim JP,1997, Establishment and characterization of human gastric carcinoma cell lines, Int J Cancer ,70, 443-449

769,Carrier F, Smith ML, Bae I, Kilpatrick KE, Lansing TJ, Chen CY, Engelstein M, Friend SH, Henner WD, Gilmer TM, Kastan MB and Fornace AJ,1994, Characterization of human gadd45, a p53-regulated protein, J Biol Chem ,269, 32672-32677

780,Jossart GH, Epstein HD, Shaver JK, Weier HU, Greulich KM, Tezelman S, Grossman RF, Siperstein AE, Duh QY and Clark OH,1996, Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines, J Clin Endocrinol Metab ,81, 3498-3504

798,Skilling JS, Squatrito RC, Connor JP, Niemann T and Buller RE,1996, p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines, Gynecol Oncol ,60, 72-80

854,Mihara K, Miyazaki M, Kondo T, Fushimi K, Tsuji T, Inoue Y, Fukaya K, Ishioka C and Namba M,1997, Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory, Acta Med Okayama ,51, 261-265

859,Ribeiro JCC, Barnetson AR, Fisher RJ, Mameghan H and Russell PJ,1997, Relationship between radiation response and p53 status in human bladder cancer cell lines, Int J Radiat Biol ,72, 760-760

864,DeFeudis P, Debernardis D, Beccaglia P, Valenti M, Sire EG, Arzani D, Stanzione S, Parodi S, Dincalci M, Russo P and Broggini M,1997, DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status, Br J Cancer ,76, 474-479

879,Xia F, Wang X, Wang YH, Tsang NM, Yandell DW, Kelsey KT and Liber HL,1995, Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines, Cancer Res ,55, 12-15

925,Pestell KE, Medlow CJ, Titley JC, Kelland LR and Walton MI,1998, Characterisation of the P53 status, Bcl-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines, Int J Cancer ,77, 913-918

963,Siddik ZH, Mims B, Lozano G and Thai G,1998, Independent pathways of p53 induction by cisplatin and X- rays in a cisplatin-resistant ovarian tumor cell line, Cancer Res ,58, 698-703

965,Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ and Kern SE,1997, Tumor-suppressive pathways in pancreatic carcinoma, Cancer Res ,57, 1731-4

982,Delia D, Goi K, Mizutani S, Yamada T, Aiello A, Fontanella E, Lamorte G, Iwata S, Ishioka C, Krajewski S, Reed JC and Pierotti MA,1997, Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations, Oncogene ,14, 2137-2147

983,Ogretmen B and Safa AR,1997, Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells, Oncogene ,14, 499-506

987,Ullrich SJ, Mercer WE and Appella E,1992, Human Wild-Type p53 Adopts a Unique Conformational and Phosphorylation State Invivo During Growth Arrest of Glioblastoma Cells, Oncogene ,7, 1635-1643

996,Eshleman JR, Casey G, Kochera ME, Sedwick WD, Swinler SE, Veigl ML, Willson JKV, Schwartz S and Markowitz SD,1998, Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53, Oncogene ,17, 719-725

999,Burger H, Nooter K, Boersma AW, Kortland CJ and Stoter G,1997, Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines, Int J Cancer ,73, 592-9

1004,Kubonishi I, Furihata M, Kamioka M, Sonobe H, Ohtsuki Y and Miyoshi I,1997, Fas-mediated apoptosis and p53 mutation in a Hodgkin's disease cell line, Br J Haematol ,98, 1048-1049

1006,Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, Shimodaira H, Niitani T, Kudo T, Akiyama M, Kimura N, Matsuo M, Mizusawa H, Tanaka N, Koyama H, Namba M, Kanamaru R and Kuroki T,1997, Screening the p53 status of human cell lines using a yeast functional assay, Mol Carcinogen ,19, 243-253

1007,Cherney BW, Bhatia KG, Sgadari C, Gutierrez MI, Mostowski H, Pike SE, Gupta G, Magrath IT and Tosato G,1997, Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells, Cancer Res ,57, 2508-2515

1011,Gelfi C, Righetti SC, Zunino F, DellaTorre G, Pierotti MA and Righetti PG,1997, Detection of p53 point mutations by double-gradient, denaturing gradient gel electrophoresis, Electrophoresis ,18, 2921-2927

1017,Moyret C, Theillet C, Puig PL, Moles JP, Thomas G and Hamelin R,1994, Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene, Oncogene ,9, 1739-43

1018,O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Jr and Kohn KW ,1997, Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer Res ,57, 4285-300

1019,Pekkola-Heino K, Servomaa K, Kiuru A and Grenman R,1996, Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma, Acta Otolaryngol (Stockh) ,116, 341-4

1023,Papp T, Jafari M and Schiffmann D,1996, Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions, J Cancer Res Clin Oncol ,122, 541-548

1030,Bae IS, Fan SJ, Bhatia K, Kohn KW, Fornace AJ and O'connor PM ,1995, Relationships between g(1) arrest and stability of the p53 and p21(Cip1/Waf1) proteins following gamma-irradiation of human lymphoma cells, Cancer Res ,55, 2387-2393

1038,Rand A, Glenn KS, Alvares CP, White MB, Thibodeau SM and Karnes WE,1996, P53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles, Cancer Lett ,98, 183-191

1042,Lin Y, Shi CY, Li B, Soo BH, Mohammed-Ali S, Wee A, Oon CJ, Mack POP and Chan SH,1996, Tumor suppressor p53 and Rb genes in human hepatocellular carcinoma, Ann Acad Med Singapore ,25, 22-30

1049,Asakawa H, Kobayashi T, Komoike Y, Yanagawa T, Takahashi M, Wakasugi E, Maruyama H, Tamaki Y, Matsuzawa Y and Monden M,1996, Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis, J Clin Endocrinol Metab ,81, 3547-52

1056,Sato M, Kawamata H, Harada K, Nakashiro K, Ikeda Y, Gohda H, Yoshida H, Nishida T, Ono K, Kinoshita M and Adachi M,1997, Induction of cyclin-dependent kinase inhibitor, p21(WAF1), by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl)- 1-piperazinyl]-2(1H)-quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene, Cancer Lett ,112, 181-189

1066,Gjerset RA, Fakhrai H, Shawler DL, Turla S, Dorigo O, Grover-Bardwick A, Mercola D, Wen SF, Collins H, Lin H and et al ,1995, Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway, In Vitro Cell Dev Biol Anim ,31, 207-14

1069,Kaino M,1997, Alterations in the tumor suppressor genes p53, RB, p16/MTS1, and p15/MTS2 in human pancreatic cancer and hepatoma cell lines, J Gastroenterol ,32, 40-6

1076,Zolzer F, Hillebrandt S and Streffer C,1995, Radiation induced g(1)-block and p53 status in six human cell lines, Radiother Oncol ,37, 20-28

1081,Loprevite M, Varesco L, Favoni R, Ferrara GB, Moro F, Ottaggio L, Fronza G, Campomenosi P, Abbondandolo A, Cutrona G, Roncella S, Albini A, Aluigi MG, Pozzi S, Pera C, Biticchi R, Gismondi V, Grossi F, Pennucci MC and Ardizzoni A,1997, Analysis of K-ras, p53, bcl-2 and Rb expression in non- small cell lung cancer cell lines, Int J Oncol ,11, 1203-1208

1098,Akasaka T, Muramatsu M, Kadowaki N, Ohno H, Ishizaki K, Yamabe H, Fukuhara S and Okuma M,1996, p53 mutation in B-cell lymphoid neoplasms with reference to oncogene rearrangements associated with chromosomal translocations, Jpn J Cancer Res ,87, 930-937

1125,Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, Konaka Y and Takatsuki K ,2000, A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation, Leukemia ,14, 922-30

1127,Morris SM, Manjanatha MG, Shelton SD, Domon OE, McGarrity LJ and Casciano DA,1996, A mutation in the p53 tumor suppressor gene of AHH-1 tk(+/- ) human lymphoblastoid cells, Mutat Res Fundam Mol Mech Mut ,356, 129-134

1143,Crook T, Parker GA, Rozycka M, Crossland S and Allday MJ,1998, A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect, Oncogene ,16, 1429-1441

1144,Barnas C, MartelPlanche G, Furukawa Y, Hollstein M, Montesano R and Hainaut P,1997, Inactivation of the p53 protein in cell lines derived from human esophageal cancers, Int J Cancer ,71, 79-87

1156,Dittmann KH, Gueven N, Mayer C, Ohneseit P, Zell R, Begg AC and Rodemann HP,1998, The presence of wild-type TP53 is necessary for the radioprotective effect of the Bowman-Birk proteinase inhibitor in normal fibroblasts, Radiat Res ,150, 648-55

1158,Zerp SF, van Elsas A, Peltenburg LT and Schrier PI,1999, p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis, Br J Cancer ,79, 921-6

1163,Markl ID and Jones PA,1998, Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer, Cancer Res ,58, 5348-53

1165,Samouelian V, Maugard CM, Jolicoeur M, Bertrand R, Arcand SL, Tonin PN, Provencher DM and Mes-Masson AM ,2004, Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A, Cancer Chemother Pharmacol ,54, 497-504

1190,McPake CR, Tillman DM, Poquette CA, George EO, Houghton JA and Harris LC,1998, Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status, Oncol Res ,10, 235-44

1204,Oh JH, Ku JL, Yoon KA, Kwon HJ, Kim WH, Park HS, Yeo KS, Song SY, Chung JK and Park JG ,1999, Establishment and characterization of 12 human colorectal- carcinoma cell lines, Int J Cancer ,81, 902-910

1207,Yoneda K, Yokoyama T, Yamamoto T, Hatabe T and Osaki T ,1999, p53 gene mutations and p21 protein expression induced independently of p53, by TGF-beta and gamma-rays in squamous cell carcinoma cells, Eur J Cancer ,35, 278-283

1216,Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, Kim SW, Park YH, Hwang JH, Yoon YB and Park JG ,2002, Establishment and characterisation of six human biliary tract cancer cell lines, Br J Cancer ,87, 187-93

1303,Lam VT, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, Hedley DW, Freedman MH, Reed JC, Malkin D and Goldenberg GJ ,1999, p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin, Leuk Res ,23, 871-880

1317,Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K and Harris CC ,1999, Mutational analysis of p73 and p53 in human cancer cell lines, Oncogene ,18, 3415-3421

1327,Wistuba, II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, Minna JD and Gazdar AF ,1999, Comparison of features of human lung cancer cell lines and their corresponding tumors, Clin Cancer Res ,5, 991-1000

1353,Marion MJ ,1998, Critical genes as early warning signs: example of vinyl chloride, Toxicol Lett ,103, 603-607

1356,Pang E, Wong N, Lai PB, To KF, Lau JW and Johnson PJ ,2000, A comprehensive karyotypic analysis on a newly developed hepatocellular carcinoma cell line, HKCI-1, by spectral karyotyping and comparative genomic hybridization, Cancer Genet Cytogenet ,121, 9-16

1363,Yufu Y, Goto T, Choi I, Uike N, Kozuru M, Ohshima K, Taniguchi T, Motokura T, Yatabe Y and Nakamura S ,1999, A new multiple myeloma cell line, MEF-1, possesses cyclin d1 overexpression and the p53 mutation, Cancer ,85, 1750-1757

1367,Takahashi M ,1998, Analyses of p53 mutations in breast cancers with a combined use of yeast functional assay and immunohistochemical staining, Hokkaido Igaku Zasshi ,73, 275-86

1373,Chansky H, Robbins JR, Cha S, Raskind WH, Conrad EU and Sandell LJ ,1998, Expression of cartilage extracellular matrix and potential regulatory genes in a new human chondrosarcoma cell line, J Orthop Res ,16, 521-30

1382,Fujita T, Kiyama M, Tomizawa Y, Kohno T and Yokota J ,1999, Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes, Int J Oncol ,15, 927-934

1386,Hayes VM, Bleeker W, Verlind E, Timmer T, Karrenbeld A, Plukker JT, Marx MP, Hofstra RM and Buys CH ,1999, Comprehensive TP53-denaturing gradient gel electrophoresis mutation detection assay also applicable to archival paraffin-embedded tissue, Diagn Mol Pathol ,8, 2-10

1393,Calistri D, Barzanti F, Dal Susino M, Fedriga R, Saragoni L, Bernardi L, Ricotti L and Zoli W ,2000, Correlation between p53 gene mutations and p53 protein accumulation evaluated by different methodologies, J Biol Regul Homeost Agents ,14, 120-7

1396,Wistuba, II, Behrens C, Milchgrub S, Syed S, Ahmadian M, Virmani AK, Kurvari V, Cunningham TH, Ashfaq R, Minna JD and Gazdar AF ,1998, Comparison of features of human breast cancer cell lines and their corresponding tumors, Clin Cancer Res ,4, 2931-8

1397,Gomez Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, Mcdonnell TJ, Steck KD, Levin VA and Yung WKA ,1996, Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis, Cancer Res ,56, 694-699

1404,Shin KH, Ku JL, Kim WH, Lee SE, Lee C, Kim SW and Park JG ,2000, Establishment and characterization of seven human renal cell carcinoma cell lines, BJU Int ,85, 130-8

1471,Anderson CW and Allalunis-Turner MJ ,2000, Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8, Radiat Res ,154, 473-6

1491,Ku JL, Yoon KA, Kim WH, Jang Y, Suh KS, Kim SW, Park YH and Park JG ,2002, Establishment and characterization of four human pancreatic carcinoma cell lines Genetic alterations in the TGFBR2 gene but not in the MADH4 gene, Cell Tissue Res ,308, 205-14

1510,Prokocimer M, Peller S, Ben-Bassat H, Goldfinger N and Rotter V ,1998, p53 gene mutation in a T-acute lymphoblastic leukemia cell line (Loucy) with t(16;20) and 5q- chromosomal aberrations, Leuk Lymphoma ,29, 607-611

1544,Telmer CA, An J, Malehorn DE, Zeng X, Gollin SM, Ishwad CS and Jarvik JW ,2003, Detection and assignment of TP53 mutations in tumor DNA using peptide mass signature genotyping, Hum Mutat ,22, 158-65

1552,Meye A, Bache M, Hinze R, Schmidt H, Wurl P, Holzhausen HJ, Rath FW and Taubert H ,1998, Molecular characterization and liposomal transfection of a p53-mutated cell line established from a poorly differentiated leiomyosarcoma, Int J Oncol ,13, 241-248

1556,Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H and Horii A ,2001, Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines, Oncol Rep ,8, 89-92

1564,Ramp U, Mahotka C, Kalinski T, Ebel E, Gabbert HE and Gerharz CD ,2001, Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types, Anticancer Res ,21, 3509-17

1570,Haapajarvi T, Kivinen L, Heiskanen A, desBordes C, Datto MB, Wang XF and Laiho M ,1999, UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53- independent manner, Exp Cell Res ,248, 272-279

1574,Komiya T, Hirashima T, Kikui M, Fukuoka M, Ohno A and Kawase I ,1999, GPI-anchored molecule-like protein (GML) expression in non-small cell lung cancer (NSCLC), Anticancer Res ,19, 4315-9

1585,Isaka K, Nishi H, Sagawa Y, Nakada T, Osakabe Y, Serizawa H, Ebihara Y and Takayama M ,2003, Establishment of a new human cell line (EN) with TP53 mutation derived from endometrial carcinoma, Cancer Genet Cytogenet ,141, 20-5

1625,Rantanen V, Grenman S, Kurvinen K, Hietanen S, Raitanen M and Syrjanen S ,1998, p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines, Gynecol Oncol ,71, 352-8

1627,Zhou M, Gu L, Yeager AM and Findley HW ,1998, Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression, Leukemia ,12, 1756-1763

1636,Hauser U, Balz V, Carey TE, Grenman R, Van Lierop A, Scheckenbach K and Bier H ,2002, Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region, Head Neck ,24, 868-73

1638,Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN and Baguley BC ,2000, Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines, Oncol Res ,12, 149-55

1653,Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppel G, Kalthoff H, Ungefroren H, Lohr M and Scarpa A ,2001, Genetic profile of 22 pancreatic carcinoma cell lines Analysis of K-ras, p53, p16 and DPC4/Smad4, Virchows Arch ,439, 798-802

1689,Koike M, Fujita F, Komori K, Katoh F, Sugimoto T, Sakamoto Y, Matsuda M and Fujita M ,2004, Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice, Cancer Sci ,95, 541-6

1703,Cinti C, Claudio PP, Luca AD, Cuccurese M, Howard CM, D'Esposito M, Paggi MG, Sala DL, Azzoni L, Halazonetis TD, Giordano A and Maraldi NM ,2000, A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T- lymphoblastoid drug resistant cell line, Oncogene ,19, 5098-105

1707,Ebina M, Martinez A, Birrer MJ and Ilona Linnoila R ,2001, In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers, Oncogene ,20, 2579-86

1710,Inokuchi K, Hamaguchi H, Taniwaki M, Yamaguchi H, Tanosaki S and Dan K ,2001, Establishment of a cell line with AML1-MTG8, TP53, and TP73 abnormalities from acute myelogenous leukemia, Genes Chromosomes Cancer ,32, 182-7

1712,Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM and Giaccone G ,2000, Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway, Clin Cancer Res ,6, 203-12

1713,Wang CS, Goulet F, Lavoie J, Drouin R, Auger F, Champetier S, Germain L and Tetu B ,2000, Establishment and characterization of a new cell line derived from a human primary breast carcinoma, Cancer Genet Cytogenet ,120, 58-72

1733,Warenius HM, Jones M, Gorman T, McLeish R, Seabra L, Barraclough R and Rudland P ,2000, Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity, Br J Cancer ,83, 1084-95

1760,Kurimoto M, Hirashima Y, Ogiichi T, Hamada H, Kamiyama H and Endo S ,2001, Establishment and characterization of a novel malignant astrocytoma cell line derived from a tumor removed in a patient with neurofibromatosis type 1, J Neurosurg ,94, 301-8

1772,Tweddle DA, Malcolm AJ, Bown N, Pearson AD and Lunec J ,2001, Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line, Cancer Res ,61, 8-13

1774,Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ and Reynolds CP ,2001, Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines, Cancer Res ,61, 6185-93

1782,Saga Y, Suzuki M, Tamura N, Ohwada M and Sato I ,2001, Establishment and characterization of a new cell line (SKS) from neuroendocrine small cell carcinoma of the uterine cervix and its chemosensitivity, Oncology ,60, 367-72

1784,Ji ZW, Oku N, Umeda M and Komori T ,2001, Establishment of an oral squamous cell carcinoma cell line (NOS-1) exhibiting amplification of the erbB-1 oncogene and point mutation of p53 tumor suppressor gene: its biological characteristics and animal model of local invasion by orthotopic transplantation of the cell line, Oral Oncol ,37, 386-92

1806,Seitz S, Wassmuth P, Fischer J, Nothnagel A, Jandrig B, Schlag PM and Scherneck S ,2002, Mutation analysis and mRNA expression of trail-receptors in human breast cancer, Int J Cancer ,102, 117-28

1819,Rapoport AP, Simons-Evelyn M, Chen T, Sidell R, Luhowskyj S, Rosell K, Obrig T, Hicks D, Hinkle PM, Nahm M, Insel RA and Abboud CN ,2001, Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes, Blood Cells Mol Dis ,27, 610-24

1842,Lai R, McDonnell TJ, O'Connor SL, Medeiros LJ, Oudat R, Keating M, Morgan MB, Curiel TJ and Ford RJ ,2002, Establishment and characterization of a new mantle cell lymphoma cell line, Mino, Leuk Res ,26, 849-55

1846,Eicheler W, Zips D, Dorfler A, Grenman R and Baumann M ,2002, Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection, J Histochem Cytochem ,50, 197-204

1854,Chen YJ, Jin YT, Shieh DB, Tsai ST and Wu LW ,2002, Molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells, Oral Oncol ,38, 699-705

1867,Sekido Y, Sato M, Usami N, Shigemitsu K, Mori S, Maeda O, Yokoi T, Hasegawa Y, Yoshioka H and Shimokata K ,2002, Establishment of a large cell lung cancer cell line (Y-ML-1B) producing granulocyte colony-stimulating factor, Cancer Genet Cytogenet ,137, 33-42

1892,Vivo C, Lecomte C, Levy F, Leroy K, Kirova Y, Renier A, Kheuang L, Piedbois P, Chopin D and Jaurand MC ,2003, Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation, Br J Cancer ,88, 388-95

1920,Narita M, Nomura J, Nakase M, Inui M, Murata T, Hamaguchi Y and Tagawa T ,2004, Characterization of the human mandibular osteoblastic osteosarcoma cell line HOSM-2 after long-term culture, Oral Oncol ,40, 742-50

1927,Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti MA and Rodolfo M ,2004, BRAF alterations are associated with complex mutational profiles in malignant melanoma, Oncogene ,23, 5968-77

1935,Kamata Y, Watanabe J, Hata H, Hamano M and Kuramoto H ,2004, Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines, Eur J Gynaecol Oncol ,25, 55-60

1937,Bohnke A, Westphal F, Schmidt A, El-Awady RA and Dahm-Daphi J ,2004, Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cells, Int J Radiat Biol ,80, 53-63

1950,Wang Y, Zhu S, Cloughesy TF, Liau LM and Mischel PS ,2004, p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition, Oncogene ,23, 1283-90

1953,Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL and Varga JL ,2003, Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin, Proc Natl Acad Sci U S A ,100, 15836-41

1967,Suzuki S, Uozumi K, Hanada S, Lin XY, Ohno N, Takatsuka Y, Takeuchi S, Owatari S, Takeshita T and Arima T ,2003, A novel c-kit positive biphenotypic acute leukemia cell line, TMBL-1, carrying a p53 point mutation, Leuk Lymphoma ,44, 849-57

1968,Johannsson OT, Staff S, Vallon-Christersson J, Kytola S, Gudjonsson T, Rennstam K, Hedenfalk IA, Adeyinka A, Kjellen E, Wennerberg J, Baldetorp B, Petersen OW, Olsson H, Oredsson S, Isola J and Borg A ,2003, Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier, Lab Invest ,83, 387-96

1976,Endoh H, Yatabe Y, Shimizu S, Tajima K, Kuwano H, Takahashi T and Mitsudomi T ,2003, RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication, Int J Cancer ,106, 45-51

1983,Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG and Carey TE ,2003, P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines, Head Neck ,25, 654-61

1991,van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ and Lucia MS ,2003, Molecular characterization of human prostate carcinoma cell lines, Prostate ,57, 205-25

1996,van Zeeburg HJ, Snijders PJ, Pals G, Hermsen MA, Rooimans MA, Bagby G, Soulier J, Gluckman E, Wennerberg J, Leemans CR, Joenje H and Brakenhoff RH ,2005, Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients, Cancer Res ,65, 1271-6

2000,Sorio C, Capelli P, Lissandrini D, Moore PS, Balzarini P, Falconi M, Zamboni G and Scarpa A ,2005, Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion, Virchows Arch ,446, 239-45

2004,Mahidhara RS, Queiroz De Oliveira PE, Kohout J, Beer DG, Lin J, Watkins SC, Robbins PD and Hughes SJ ,2005, Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma, J Surg Res ,123, 302-11

2019,Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM, Palmer JM and Hayward NK ,1994, Mutation and expression of the p53 gene in human malignant melanoma, Melanoma Res ,4, 35-45

2020,Kichina JV, Rauth S, Das Gupta TK and Gudkov AV ,2003, Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53, Oncogene ,22, 4911-7

2021,Bergqvist M, Brattstrom D, Gullbo J, Hesselius P, Brodin O and Wagenius G ,2003, p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer, Anticancer Res ,23, 1207-12

2029,Concin N, Zeillinger C, Tong D, Stimpfl M, Konig M, Printz D, Stonek F, Schneeberger C, Hefler L, Kainz C, Leodolter S, Haas OA and Zeillinger R ,2003, Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines, Breast Cancer Res Treat ,79, 37-46

2032,Henderson YC, Wang E and Clayman GL ,1998, Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in head and neck squamous cell carcinomas, Laryngoscope ,108, 1553-6

2048,Felix CA, Megonigal MD, Chervinsky DS, Leonard DGB, Tsuchida N, Kakati S, Block AMW, Fisher J, Grossi M, Salhany KI, JaniSait SN and Aplan PD ,1998, Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukemia, Blood ,91, 4451-4456

2049,Nagai M, Fujita M, Ikeda T, Ohmori M, Kuwabara H, Yamaoka G, Tanaka K, Kamada N, Taniwaki M, Inoue T, Irino S and Takahara J ,1997, Alterations of p53 and Rb genes in a novel human GM-CSF- dependent myeloid cell line (OHN-GM) established from therapy-related leukaemia, Br J Haematol ,98, 392-398

2051,Liu Yand Bodmer W F ,2006, Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines, Proc Natl Acad Sci U S A ,103, 976-81

2068,Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, Dricu A, Lundeberg J, Wejde J, Bartolazzi A, Wiman K G, and Larsson O ,2000, Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact, Cancer Res ,60, 5278-83

2078,Sonobe H, Takeuchi T, Furihata M, Taguchi T, Kawai A, Ohjimi Y, Iwasaki H, Kaneko Y, and Ohtsuki Y ,2000, A new human malignant peripheral nerve sheath tumour-cell line, HS-sch- 2, harbouring p53 point mutation [In Process Citation], Int J Oncol ,17, 347-52

2087,Takata M, Hashimoto K, Mehregan P, Lee MW, Yamamoto A, Mohri S, Ohara K, Takehara K ,2000, Genetic changes in sweat gland carcinomas, J Cutan Pathol ,27, 30-35

2088,Van Gele M, Kaghad M, Leonard JH, Van Roy N, Naeyaert JM, Geerts ML, Van Belle S, Cocquyt V, Bridge J, Sciot R, De Wolf-Peeters C, De Paepe A, Caput D, Speleman F ,2000, Mutation analysis of P73 and TP53 in Merkel cell carcinoma, Br J Cancer ,82, 823-826

2091,Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M ,2006, Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines, Breast Cancer Res Treat ,99, 97-101

2096,Sugiyama H, Arita M, Min Z, Zhong X, Iwasaki I, Hirano K, Shimatake H, Hemmi H ,2003, A novel dysfunctional p53 mutation in the human neuroblastoma cell line TGW, Tohoku J Exp Med ,201, 229-237

2106,Halatsch ME, Gehrke EE, Vougioukas VI, Botefur IC, A-Borhani F, Efferth T, Gebhart E, Domhof S, Schmidt U, Buchfelder M ,2004, Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines, J Neurosurg ,100, 523-533

2116,Eisold S, Ryschich E, Linnebacher M, Giese T, Nauheimer D, Wild A, Bartsch DK, Buchler MW, Schmidt J ,2004, Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background, Cancer ,100, 1978-1986

2160,Lindkvist A, Franzen A, Ren ZP, Heldin NE, Paulsson-Karlsson Y ,2005, Differential effects of TGF-beta1 on telomerase activity in thyroid carcinoma cell lines, Biochem Biophys Res Commun ,338, 1625-1633

2189,Lee EJ, Kim J, Lee SA, Kim EJ, Chun YC, Ryu MH, Yook JI ,2005, Characterization of newly established oral cancer cell lines derived from six squamous cell carcinoma and two mucoepidermoid carcinoma cells, Exp Mol Med ,37, 379-390

2195,Thiery J, Abouzahr S, Dorothee G, Jalil A, Richon C, Vergnon I, Mami-Chouaib F, Chouaib S ,2005, p53 potentiation of tumor cell susceptibility to CTL involves Fas and mitochondrial pathways, J Immunol ,174, 871-878

2198,Smardova J, Pavlova S, Svitakova M, Grochova D, Ravcukova B ,2005, Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124, Oncol Rep ,14, 901-907

2207,Chen S, Xue Y, Zhang X, Wu Y, Pan J, Wang Y, Ceng J ,2005, A new human acute monocytic leukemia cell line SHI-1 with t(6;11)(q27;q23), p53 gene alterations and high tumorigenicity in nude mice, Haematologica ,90, 766-775

2224,Lin SC, Liu CJ, Chiu CP, Chang SM, Lu SY and Chen YJ ,2004, Establishment of OC3 oral carcinoma cell line and identification of NF-kappa B activation responses to areca nut extract, J Oral Pathol Med ,33, 79-86

2231,Kudo Y, Ogawa I, Kitagawa M, Kitajima S, Samadarani Siriwardena BS, Aobara N, Matsuda C, Miyauchi M, Takata T ,2006, Establishment and characterization of a spindle cell squamous carcinoma cell line, J Oral Pathol Med S ,35, 479-483

2242,Murai Y, Hayashi S, Takahashi H, Tsuneyama K, Takano Y ,2005, Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines, Pathol Res Pract ,201, 109-115

2245,Mandic R, Schamberger CJ, Muller JF, Geyer M, Zhu L, Carey TE, Grenman R, Dunne AA, Werner JA ,2005, Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53, Clin Cancer Res ,11, 6845-6852

2247,Bhatia K, Goldschmidts W, Gutierrez M, Gaidano G, Dalla-Favera R, Magrath I ,1993, Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect, FASEB J ,7, 951-956

2248,Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, Chen J, Wang S, Bradford CR, Carey TE ,2005, Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL, Mol Cancer Ther ,4, 1096-1104

2249,Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA, Stratton MR ,2006, COSMIC 2005, Br J Cancer ,94, 318-322

2250,Servomaa K, Kiuru A, Grenman R, Pekkola-Heino K, Pulkkinen JO, Rytomaa T ,1996, p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines, Cell Prolif ,29, 219-230

2251,Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, Hamelin R ,2001, Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines, Oncogene ,20, 5025-5032

3000, Wolf D, Rotter V (1985) Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A 82: 790-794.

3001, Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB, Gudkov AV (2003) Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res 63: 2905-2912.

Cell lines database

References